MicroRNA-145 restores contractile vascular smooth muscle phenotype and coronary collateral growth in the metabolic syndrome

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 4, 2013, Pages 727-736

  Hutcheson, Rebecca ^a   Terry, Russell ^a   Chaplin, Jennifer ^a   Smith, Erika ^a   Musiyenko, Alla ^a   Russell, James C ^b   Lincoln, Thomas ^a   Rocic, Petra ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

collateral circulation; metabolic syndrome; microRNA; vascular smooth muscle phenotype

Indexed keywords

ADENOVIRUS VECTOR; CONTRACTILE PROTEIN; MICRORNA 145; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY OBSTRUCTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; METABOLIC SYNDROME X; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE CONTRACTION; VASCULAR SMOOTH MUSCLE;

ADENOVIRIDAE; ANIMALS; COLLATERAL CIRCULATION; CORONARY CIRCULATION; CORONARY VESSELS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; MALE; METABOLIC SYNDROME X; MICRORNAS; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; TIME FACTORS; VASOCONSTRICTION;

EID: 84875363803     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.301116     Document Type: Article

References (31)

1. Seiler C. The human coronary collateral circulation. Heart. 2003;89:1352-1357.
2. Chen W, Gabel S, Steenbergen C, Murphy E. A redox-based mechanism for cardioprotection induced by ischemic preconditioning in perfused rat heart. Circ Res. 1995;77:424-429.
3. Reed R, Kolz C, Potter B, Rocic P. The mechanistic basis for the disparate effects of angiotensin II on coronary collateral growth. Arterioscler Thromb Vasc Biol. 2008;28:61-67.
4. Matsunaga T, Warltier DC, Weihrauch DW, Moniz M, Tessmer J, Chilian WM. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation. 2000;102:3098-3103.
5. Sasmaz H, Yilmaz MB. Coronary collaterals in obese patients: impact of metabolic syndrome. Angiology. 2009;60:164-168.
6. Yilmaz MB, Caldir V, Guray Y, Guray U, Altay H, Demirkan B, Cay S, Kisacik HL, Korkmaz S. Relation of coronary collateral vessel development in patients with a totally occluded right coronary artery to the metabolic syndrome. Am J Cardiol. 2006;97:636-639.
7. Turhan H, Yasar AS, Erbay AR, Yetkin E, Sasmaz H, Sabah I. Impaired coronary collateral vessel development in patients with metabolic syndrome. Coron Artery Dis. 2005;16:281-285.
8. Mouquet F, Cuilleret F, Susen S, Sautière K, Marboeuf P, Ennezat PV, McFadden E, Pigny P, Richard F, Hennache B, Vantyghem MC, Bertrand M, Dallongeville J, Jude B, Van Belle E. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur Heart J. 2009;30: 840-849.
9. Dodd T, Jadhav R, Wiggins L, Stewart J, Smith E, Russell JC, Rocic P. MMPs 2 and 9 are essential for coronary collateral growth and are prominently regulated by p38 MAPK. J Mol Cell Cardiol. 2011;51:1015-1025.
10. Schaper W. Collateral circulation: past and present. Basic Res Cardiol. 2009;104:5-21.
11. Russell JC, Graham SE, Richardson M. Cardiovascular disease in the JCR:LA-cp rat. Mol Cell Biochem. 1998;188:113-126.
12. Kumar MS, Owens GK. Combinatorial control of smooth musclespecific gene expression. Arterioscler Thromb Vasc Biol. 2003;23: 737-747.
13. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460:705-710.
14. Albinsson S, Sessa WC. Can microRNAs control vascular smooth muscle phenotypic modulation and the response to injury? Physiol Genomics. 2011;43:529-533.
15. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, Deitch EA, Huo Y, Delphin ES, Zhang C. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009;105:158-166.
16. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107:677-684.
17. Iwata H, Sata M. Origin of cells that contribute to neointima growth. Circulation. 2008;117:3060-3061.
18. Boettger T, Beetz N, Kostin S, Schneider J, Krüger M, Hein L, Braun T. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest. 2009;119:2634-2647.
19. Caruso P, Dempsie Y, Stevens HC, et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res. 2012;111:290-300.
20. Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 2011;8:125-131.
21. Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T, Seki N. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011;38: 1093-1101.
22. Yin R, Zhang S, Wu Y, Fan X, Jiang F, Zhang Z, Feng D, Guo X, Xu L. microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. Oncol Rep. 2011;25:1747-1754.
23. Miano J. Vascular smooth muscle cell differentiation. J Biomed Res. 2010;24:169-180
24. Cullingford TE, Butler MJ, Marshall AK, Tham el L, Sugden PH, Clerk A. Differential regulation of Krüppel-like factor family transcription factor expression in neonatal rat cardiac myocytes: effects of endothelin-1, oxidative stress and cytokines. Biochim Biophys Acta. 2008;1783:1229-1236.
25. Cai WJ, Kocsis E, Wu X, Rodríguez M, Luo X, Schaper W, Schaper J. Remodeling of the vascular tunica media is essential for development of collateral vessels in the canine heart. Mol Cell Biochem. 2004;264:201-210.
26. O'Brien SF, Russell JC, Dolphin PJ, Davidge ST. Vascular wall function in insulin-resistant JCR:LA-cp rats: role of male and female sex. J Cardiovasc Pharmacol. 2000;36:176-181.
27. Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJ, Zeiher AM, Scheffer MP, Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, Boon RA, Dimmeler S. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol. 2012;14:249-256.
28. Jadhav R, Dodd T, Smith E, Bailey E, Delucia AL, Russell JC, Madison R, Potter B, Walsh K, Jo H, Rocic P. Angiotensin type I receptor blockade in conjunction with enhanced Akt activation restores coronary collateral growth in the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2011;300:H1938-H1949.
29. Reed R, Potter B, Smith E, Jadhav R, Villalta P, Jo H, Rocic P. Redoxsensitive Akt and Src regulate coronary collateral growth in metabolic syndrome. Am J Physiol Heart Circ Physiol. 2009;296:H1811-H1821.
30. Sung SH, Wu TC, Huang CH, Lin SJ, Chen JW. Prognostic impact of body mass index in patients undergoing coronary artery bypass surgery. Heart. 2011;97:648-654.
31. Hu R, Ma CS, Nie SP, et al. Effect of metabolic syndrome on prognosis and clinical characteristics of revascularization in patients with coronary artery disease. Chin Med J. 2006;119:1871-1876.